Clinical Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 902, February 1, 2007. doi: 10.1158/1078-0432.CCR-06-2363
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobayashi, N.
Right arrow Articles by Hirohashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, N.
Right arrow Articles by Hirohashi, S.

Imaging, Diagnosis, Prognosis

FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis

Noritoshi Kobayashi1, Nobuyoshi Hiraoka1, Wataru Yamagami1, Hidenori Ojima1, Yae Kanai1, Tomoo Kosuge2, Atsushi Nakajima3 and Setsuo Hirohashi1

Authors' Affiliations: 1 Pathology Division, National Cancer Center Research Institute; 2 Division of Hepato-Biliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan; and 3 Gastroenterology Division, Yokohama City University Hospital, Yokohama, Japan

Requests for reprints: Nobuyoshi Hiraoka, Pathology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-33542-2511; Fax: 81-33248-2463; E-mail: nhiraoka{at}gan2.res.ncc.go.jp.

Purpose: Tumor-infiltrating lymphocytes represent the host immune response to cancer. CD4+CD25+FOXP3+ regulatory T cells (Tregs) suppress the immune reaction. The aim of the present study was to investigate the clinicopathologic significance and roles of Tregs and CD8+ T cells during hepatocarcinogenesis.

Experimental Design: We examined the infiltration of FOXP3+ Tregs and CD8+ T cells in the tumor stroma and nontumorous liver parenchyma using 323 hepatic nodules including precursor lesions, early hepatocellular carcinoma (HCC), and advanced HCC, along with 39 intrahepatic cholangiocarcinomas and 59 metastatic liver adenocarcinomas. We did immunohistochemical comparative studies.

Results: The prevalence of Tregs was significantly higher in HCC than in the nontumorous liver (P < 0.001). The patient group with a high prevalence of Tregs infiltrating HCC showed a significantly lower survival rate (P = 0.007). Multivariate analysis revealed that the prevalence of Tregs infiltrating HCC was an independent prognostic factor. The prevalence of Tregs increased in a stepwise manner (P < 0.001) and that of CD8+ T cells decreased during the progression of hepatocarcinogenesis (P < 0.001). Regardless of the presence of hepatitis virus infection or histopathologic evidence of hepatitis, the prevalence of Tregs was significantly increased in nontumorous liver bearing primary hepatic tumors.

Conclusions: Tregs play a role in controlling the immune response to HCC during the progression of hepatocarcinogenesis. It has been suggested that primary hepatic cancers develop in liver that is immunosuppressed by a marked infiltration of Tregs. A high prevalence of Tregs infiltrating HCC is thought to be an unfavorable prognostic indicator.




This article has been cited by other articles:


Home page
JCOHome page
C. Badoual, S. Hans, W. H. Fridman, D. Brasnu, S. Erdman, and E. Tartour
Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer
J. Clin. Oncol., July 1, 2009; 27(19): e5 - e6.
[Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-C. Lin, L.-Y. Chang, C.-T. Huang, H.-M. Peng, A. Dutta, T.-C. Chen, C.-T. Yeh, and C.-Y. Lin
Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity
J. Immunol., May 15, 2009; 182(10): 6095 - 6104.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Gobert, I. Treilleux, N. Bendriss-Vermare, T. Bachelot, S. Goddard-Leon, V. Arfi, C. Biota, A. C. Doffin, I. Durand, D. Olive, et al.
Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
Cancer Res., March 1, 2009; 69(5): 2000 - 2009.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta
Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
J. Clin. Oncol., January 10, 2009; 27(2): 186 - 192.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. L. Marshall
Time to Shift the Focus of the War: It Is Not All About the Enemy
J. Clin. Oncol., January 10, 2009; 27(2): 168 - 169.
[Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Sakai, M. Honda, H. Fujinaga, I. Tatsumi, E. Mizukoshi, Y. Nakamoto, and S. Kaneko
Common Transcriptional Signature of Tumor-Infiltrating Mononuclear Inflammatory Cells and Peripheral Blood Mononuclear Cells in Hepatocellular Carcinoma Patients
Cancer Res., December 15, 2008; 68(24): 10267 - 10279.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Abou-Ghazal, D. S. Yang, W. Qiao, C. Reina-Ortiz, J. Wei, L.-Y. Kong, G. N. Fuller, N. Hiraoka, W. Priebe, R. Sawaya, et al.
The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas
Clin. Cancer Res., December 15, 2008; 14(24): 8228 - 8235.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al.
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Dolganiuc and G. Szabo
T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't
J. Leukoc. Biol., September 1, 2008; 84(3): 614 - 622.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Gil-Guerrero, J. Dotor, I. L. Huibregtse, N. Casares, A. B. Lopez-Vazquez, F. Rudilla, J. I. Riezu-Boj, J. Lopez-Sagaseta, J. Hermida, S. Van Deventer, et al.
In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-{beta}1
J. Immunol., July 1, 2008; 181(1): 126 - 135.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. H. Schreiber
The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1931 - 1934.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Yakirevich and M. B. Resnick
Regulatory T Lymphocytes: Pivotal Components of the Host Antitumor Response
J. Clin. Oncol., June 20, 2007; 25(18): 2506 - 2508.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.